These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 33227451)

  • 1. Innovative trial designs and analyses for vaccine clinical development.
    Liu M; Li Q; Lin J; Lin Y; Hoffman E
    Contemp Clin Trials; 2021 Jan; 100():106225. PubMed ID: 33227451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering Antiviral Vaccines.
    Zhou X; Jiang X; Qu M; Aninwene GE; Jucaud V; Moon JJ; Gu Z; Sun W; Khademhosseini A
    ACS Nano; 2020 Oct; 14(10):12370-12389. PubMed ID: 33001626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovative Designs, Methods and Application for Disease Risk Prediction and Drug Development: Frequentist, Bayesian, and Beyond.
    Contemp Clin Trials; 2017 Dec; 63():1. PubMed ID: 29153293
    [No Abstract]   [Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerating Vaccine Development During the 2013-2016 West African Ebola Virus Disease Outbreak.
    Higgs ES; Dubey SA; Coller BAG; Simon JK; Bollinger L; Sorenson RA; Wilson B; Nason MC; Hensley LE
    Curr Top Microbiol Immunol; 2017; 411():229-261. PubMed ID: 28918539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine clinical trials with dynamic borrowing of historical controls: Two retrospective studies.
    Callegaro A; Karkada N; Aris E; Zahaf T
    Pharm Stat; 2023; 22(3):475-491. PubMed ID: 36606496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations on the clinical development of COVID-19 vaccine from trial design perspectives.
    Jiang Z; Wang X; Xia J
    Hum Vaccin Immunother; 2021 Mar; 17(3):656-660. PubMed ID: 32991223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethical considerations for epidemic vaccine trials.
    Monrad JT
    J Med Ethics; 2020 Jul; 46(7):465-469. PubMed ID: 32414757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations.
    Manoharan L; Olliaro P; Horby PW; Watson CH
    Trials; 2021 May; 22(1):370. PubMed ID: 34051840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress and challenge of vaccine development against 2019-novel coronavirus (2019-nCoV)].
    Shi Y; Wang N; Zou QM
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Jun; 54(6):614-619. PubMed ID: 32234130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 Vaccine Development to Vaccination.
    Pandey A; Belbase P; Parajuli A
    J Nepal Health Res Counc; 2021 Jan; 18(4):807-809. PubMed ID: 33510536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calling for an exponential escalation scheme in vaccine development for COVID-19.
    Wehling M
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1471-1472. PubMed ID: 32548679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
    Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
    Trials; 2014 Feb; 15():68. PubMed ID: 24571662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
    Bennet BM; Wolf J; Laureano R; Sellers RS
    Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned.
    Zola Matuvanga T; Larivière Y; Lemey G; De Bie J; Milolo S; Meta R; Esanga E; Vermeiren PP; Thys S; Van Geertruyden JP; Van Damme P; Maketa V; Matangila J; Mitashi P; Muhindo-Mavoko H
    Vaccine; 2022 May; 40(25):3470-3480. PubMed ID: 35550847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping time use in clinical trials for vaccines against emerging infectious diseases.
    Mandi H; Yimer SA; Norheim G
    Clin Trials; 2021 Jun; 18(3):286-294. PubMed ID: 33653146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian adaptive clinical trial designs for respiratory medicine.
    Ryan EG; Couturier DL; Heritier S
    Respirology; 2022 Oct; 27(10):834-843. PubMed ID: 35918280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.
    MacPherson A; Hutchinson N; Schneider O; Oliviero E; Feldhake E; Ouimet C; Sheng J; Awan F; Wang C; Papenburg J; Basta NE; Kimmelman J
    Ann Intern Med; 2021 Mar; 174(3):326-334. PubMed ID: 33226855
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.